arrow
T

Thibaud Valentin

Institut Claudius Regaud
H指数:18
被引数:1,143

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial

对于新诊断的多发性转移性尤因肉瘤患者,采用序贯多模式治疗方法的临床价值:法国前瞻性CombinaiR3 II期试验结果

2025-11-170
PRE
Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life national setting over a decade

转移性骨肉瘤,真实世界国家背景下一十年来患者的治疗模式与结局

2025-09-280
PRE
Outcome of 1773 superficial non-dermatofibrosarcoma sarcomas A French Sarcoma Group study (FSG) from the NETSARC database

1773例非皮肤纤维肉瘤浅表肉瘤的结局:一项来自NETSARC数据库的法国肉瘤组(FSG)研究

2025-09-120
PRE
Clinical presentation, management and outcome of 11,132 patients with liposarcoma patients: a population-based study from the NETSARC+ registry

临床表现、治疗管理及结局:11,132例脂肪肉瘤患者的流行病学研究(基于NETSARC+登记系统)

2025-07-310
PREAI
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab

用抗血管生成药物重塑冷软组织肉瘤的肿瘤微环境: regorafenib联合avelumab的2期试验

2025-06-270
OA
Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy

林奇综合征患者中发生的肉瘤富集于多形性软组织肉瘤,并且对免疫疗法敏感。

2025-02-011
PRE
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?
2024-10-080
PRE
Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma
2024-08-010
OAAI
Improved nationwide survival of sarcoma patients with a network of reference centers
2024-04-019
OA
PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent
CANCER
IF5.1
2024-03-122
OAAI
Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC plus series of 330 patients over 13 years
2024-01-013
OA
Differential presentation and outcome of sclerosing epithelioid fibrosarcoma (SEF) vs low grade fibromyxoid sarcoma (LGFMS): The nationwide series of 330 patients in NETSARC since 2010
2023-10-010
OA
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years
2023-10-0111
OA